KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Amortization of Deferred Charges: 2016-2024

Historic Amortization of Deferred Charges for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to $29.1 million.

  • Amneal Pharmaceuticals' Amortization of Deferred Charges fell 37.34% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.5 million, marking a year-over-year decrease of 5.24%. This contributed to the annual value of $29.1 million for FY2024, which is 151.97% up from last year.
  • According to the latest figures from FY2024, Amneal Pharmaceuticals' Amortization of Deferred Charges is $29.1 million, which was up 151.97% from $11.5 million recorded in FY2023.
  • Amneal Pharmaceuticals' 5-year Amortization of Deferred Charges high stood at $29.1 million for FY2024, and its period low was $8.6 million during FY2022.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was $11.5 million (2023), whereas its average is $16.4 million.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Amortization of Deferred Charges declined by 6.61% in 2022, and later soared by 151.97% in 2024.
  • Over the past 5 years, Amneal Pharmaceuticals' Amortization of Deferred Charges (Yearly) stood at $8.7 million in 2020, then grew by 6.05% to $9.2 million in 2021, then decreased by 6.61% to $8.6 million in 2022, then soared by 34.36% to $11.5 million in 2023, then spiked by 151.97% to $29.1 million in 2024.